Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy
PPIs were prescribed in 2,418 patients (83.1%) with the no-aspirin strategy, and in 2,695 patients (92.5%) with the aspirin strategy. In the propensity score matched cohort (no-aspirin strategy: n = 902 and aspirin strategy: n = 376), a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke more often occurred in the PPI group than in the no-PPI group with the no-aspirin strategy (7.1% vs 2.4%, P = 0.002), but not with the aspirin strategy (6.9% vs 7.4%, P = 0.817). Death also more often occurred in the PPI group than in the no-PPI group with the no-aspirin strategy, but not with the aspirin strategy. Incidence of major bleeding was not different between the groups regardless of the no-aspirin and aspirin strategies (5.5% vs 3.3%, P = 0.150, and 6.9% vs 4.3%, P = 0.278) CONCLUSIONS: PPI use was associated with higher risks of cardiovascular events and mortality without decreasing major bleeding in patients undergoing PCI with aspirin-free P2Y<sub>12</sub> inhibitor monotherapy. (ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; NCT04609111).
Authors
- Koh Ono (ORCID: https://orcid.org/0000-0002-4163-980X)
- Yuki Obayashi (ORCID: https://orcid.org/0000-0002-0387-8877)
- Kazuya Kawai (ORCID: https://orcid.org/0000-0003-0464-1414)
- Akihiro Takasaki (ORCID: https://orcid.org/0000-0003-0641-6464)
- Kiyoshi Hibi (ORCID: https://orcid.org/0000-0002-1543-1183)
- Nobuya Higashitani
- Tsuyoshi Isawa (ORCID: https://orcid.org/0000-0003-1271-0344)
- Kohei Wakabayashi (ORCID: https://orcid.org/0000-0003-4264-0439)
- Y Onishi (ORCID: https://orcid.org/0009-0001-7824-6911)
- Kenji Andò (ORCID: https://orcid.org/0000-0003-0699-4248)
- Tsutomu Murakami (ORCID: https://orcid.org/0000-0002-5164-1620)
- Hirotoshi Watanabe (ORCID: https://orcid.org/0000-0002-9443-5915)
- Satoru Suwa (ORCID: https://orcid.org/0000-0002-7614-0937)
- Takeshi Morimoto (ORCID: https://orcid.org/0000-0002-6844-739X)
- Tenjin Nishikura (ORCID: https://orcid.org/0000-0001-5876-1169)
- Masahiro Natsuaki (ORCID: https://orcid.org/0000-0002-0189-2317)
- Tetsuya Ishikawa (ORCID: https://orcid.org/0000-0003-2765-5165)
- Masataka Nakano (ORCID: https://orcid.org/0000-0002-3569-9371)
- Ko Yamamoto
- Ryusuke Nishikawa
- Tomoya Kimura (ORCID: https://orcid.org/0009-0005-5575-9035)
- Hiroyuki Takenaka
- Takeshi Kimura
Institutions
- Saga University (JP)
- Kyoto University (JP)
- Yokohama City University Medical Center (JP)
- Chikamori Hospital (JP)
- Hiratsuka Kyosai Hospital (JP)
- Tokai University Hospital (JP)
- Mie University Hospital (JP)
- Juntendo University Shizuoka Hospital (JP)
- Otsu Red Cross Hospital (JP)
- Dokkyo Medical University Saitama Medical Center (JP)
- Hakodate Central General Hospital (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- SHOWA Medical University Hospital (JP)
- Kokura Memorial Hospital (JP)
- Municipal Hirakata City Hospital (JP)
- Sendai Kousei Hospital (JP)
- Hyogo University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- JACC Asia
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.jacasi.2025.09.015
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39